Mary Szela Purchases 39,682 Shares of TriSalus Life Sciences (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela purchased 39,682 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $2.59 per share, for a total transaction of $102,776.38. Following the transaction, the chief executive officer directly owned 1,065,215 shares in the company, valued at approximately $2,758,906.85. This represents a 3.87% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $3.15 on Wednesday. The company has a market cap of $193.13 million, a PE ratio of -2.23 and a beta of 0.56. The firm’s 50 day moving average price is $4.11 and its 200-day moving average price is $5.10. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78. TriSalus Life Sciences, Inc. has a 52-week low of $2.20 and a 52-week high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. Sell-side analysts forecast that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TLSI shares. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Lake Street Capital reduced their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Finally, Canaccord Genuity Group decreased their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 6th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.50.

Hedge Funds Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in TLSI. Goldman Sachs Group Inc. acquired a new stake in shares of TriSalus Life Sciences in the first quarter valued at about $187,000. Geode Capital Management LLC boosted its position in TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after acquiring an additional 235,627 shares during the last quarter. JPMorgan Chase & Co. boosted its position in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $47,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.